Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.24.2.u1
Commitments and Contingencies (Details)
£ in Millions
 12 Months Ended
Apr. 03, 2024
USD ($)
May 31, 2024
USD ($)
item
May 31, 2024
GBP (£)
Side Letter Agreement With Samsung      
Commitments and Contingencies      
Past due balance $ 43,800,000    
Contractual obligation, non contingent amount $ 250,000 $ 250,000  
Contractual obligation, percentage of qualifying revenue agreed to pay 20.00%    
Amount of gain recognized   0  
Amount of contractual obligation included in other liabilities   43,500,000  
Progenics Purchase Agreement      
Commitments and Contingencies      
Amount of milestone payments payable   $ 5,000,000  
Percentage of royalty payable   3.50%  
Amount payable upon filing BLA with FDA   $ 500,000  
Amount payable upon FDA approval   500,000  
Annual maintenance fees   $ 150,000  
Progenics Purchase Agreement | Royalty Payable in Initial 10 Years      
Commitments and Contingencies      
Percentage of royalty payable   5.00%  
Lonza Agreement      
Commitments and Contingencies      
Number of contract manufacturers | item   2  
Annual license fee   $ 350,000 £ 0.3
Royalty on net sales (as a percent)   2.00% 2.00%